Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity

Scott, Pippa; Moss, William J; Gilani, Zunera; Low, Nicola (2011). Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. Journal of infectious diseases, 204 Suppl 1, S164-S178. Cary, N.C.: Oxford University Press 10.1093/infdis/jir071

	Text Scott JInfectDis 2011.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (559kB)
Preview	Text jir071.pdf - Other Available under License Publisher holds Copyright. Download (569kB) | Preview

Background. Measles control may be more challenging in regions with a high prevalence of HIV infection. HIV-infected children are likely to derive particular benefit from measles vaccines because of an increased risk of severe illness. However, HIV infection can impair vaccine effectiveness and may increase the risk of serious adverse events after receipt of live vaccines. We conducted a systematic review to assess the safety and immunogenicity of measles vaccine in HIV-infected children.

Methods. The authors searched 8 databases through 12 February 2009 and reference lists. Study selection and data extraction were conducted in duplicate. Meta-analysis was conducted when appropriate.

Results. Thirty-nine studies published from 1987 through 2008 were included. In 19 studies with information about measles vaccine safety, more than half reported no serious adverse events. Among HIV-infected children, 59% (95% confidence intervals [CI], 46–71%) were seropositive after receiving standard-titer measles vaccine at 6 months (1 study), comparable to the proportion of seropositive HIV-infected children vaccinated at 9 (8 studies) and 12 months (10 studies). Among HIV-exposed but uninfected and HIV-unexposed children, the proportion of seropositive children increased with increasing age at vaccination. Fewer HIV-infected children were protected after vaccination at 12 months than HIV-exposed but uninfected children (relative risk, 0.61; 95% CI, .50–.73).

Conclusions. Measles vaccines appear to be safe in HIV-infected children, but the evidence is limited. When the burden of measles is high, measles vaccination at 6 months of age is likely to benefit children of HIV-infected women, regardless of the child's HIV infection status.

Interest & Impact

Downloads

174 since deposited on 04 Oct 2013
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item